New Study Finds Alzheimer’s Outranks Cancer, Infectious Diseases such as COVID-19, Stroke and Heart Attack as Most-Feared Chronic Disease by Retirees
UsAgainstAlzheimer’s issued the following statement on the latest findings in the 2020 Edward Jones/Age Wave The Four Pillars of New Retirement study.
July 30, 2020
UsAgainstAlzheimer’s Hails New Lancet Commission Findings that Up to 40 Percent of Dementia Cases Could be Prevented or Delayed
UsAgainstAlzheimer’s (UsA2) today applauded The Lancet Commission’s release of new research showing that managing certain risk factors could prevent or delay around 40 percent of worldwide dementia cases.
July 29, 2020
New UsAgainstAlzheimer’s Research Shows What Matters Most to Patients and Caregivers in Drug Treatments
UsAgainstAlzheimer’s (UsA2) today released five publications delivering first-of-their kind findings on outcomes from dementia treatments and therapies that matter most to individuals with Alzheimer’s and those who care for them.
July 28, 2020
UsA2 Statement on Promising New Research on Blood Tests for Alzheimer's
July 8, 2020
UsAgainstAlzheimer’s Calls Biogen Submission of Alzheimer’s Treatment for FDA Review and Approval an Exciting Step Forward
George Vradenburg, chairman and co-founder of UsAgainstAlzheimer’s, issued the following statement.
February 10, 2020
UsAgainstAlzheimer’s Statement on Disappointing Results from DIAN-TU Clinical Trial
UsAgainstAlzheimer’s today released the following statement regarding the negative results of anti-amyloid Alzheimer's drug therapies of Eli Lilly and of Roche and its U.S. affiliate Genetech.
January 22, 2020
New Partnership to Accelerate the Fight Against Alzheimer’s Disease
World Economic Forum will partner over the next year with the Global CEO Initiative (CEOi) to form a Coalition to accelerate treatments for Alzheimer’s Disease
November 13, 2019
UsAgainstAlzheimer’s Launches Online Biomarkers Repository to Track Alzheimer’s Research
Constantly-evolving Biomarkers Repository to help policymakers, healthcare system leaders and scientific community better understand and support personalized medicine
It’s been an exciting few weeks in the Alzheimer’s world – a world that hasn’t seen a new drug in 15 years. All of the activity has raised a lot of questions around the world’s progress towards a cure.
